0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Macular Degeneration Drug Pipeline - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: November 2024
|
Report Code: QYRE-Auto-16N5013
Home | Market Reports | Health| Vision Care
Global Macular Degeneration Drug Pipeline Market Insights Forecast to 2028
BUY CHAPTERS

Macular Degeneration Drug Pipeline - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-16N5013
Report
November 2024
Pages:157
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Macular Degeneration Drug Pipeline - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Macular Degeneration Drug Pipeline - Market

Macular Degeneration Drug Pipeline - Market

The global market for Macular Degeneration Drug Pipeline was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Macular Degeneration Drug Pipeline, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Macular Degeneration Drug Pipeline by region & country, by Type, and by Application.
The Macular Degeneration Drug Pipeline market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration Drug Pipeline.
Market Segmentation

Scope of Macular Degeneration Drug Pipeline - Market Report

Report Metric Details
Report Name Macular Degeneration Drug Pipeline - Market
CAGR 5%
Segment by Type:
  • Gene therapy
  • Small molecules
  • Stem cell therapy
  • Gene therapies
Segment by Application
  • Hospital
  • Research Institute
  • Commercial
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq AG, Sinocelltech, RemeGen, Grifols, S.A., Kyowa Kirin, EyePoint Pharmaceutical, IVERIC Bio, Kodiak Sciences, Ribomic, Lineage Cell Therapeutics, Graybug Vision, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Outlook Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Macular Degeneration Drug Pipeline manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Macular Degeneration Drug Pipeline in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Macular Degeneration Drug Pipeline in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Macular Degeneration Drug Pipeline - Market report?

Ans: The main players in the Macular Degeneration Drug Pipeline - Market are Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq AG, Sinocelltech, RemeGen, Grifols, S.A., Kyowa Kirin, EyePoint Pharmaceutical, IVERIC Bio, Kodiak Sciences, Ribomic, Lineage Cell Therapeutics, Graybug Vision, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Outlook Therapeutics

What are the Application segmentation covered in the Macular Degeneration Drug Pipeline - Market report?

Ans: The Applications covered in the Macular Degeneration Drug Pipeline - Market report are Hospital, Research Institute, Commercial, Other

What are the Type segmentation covered in the Macular Degeneration Drug Pipeline - Market report?

Ans: The Types covered in the Macular Degeneration Drug Pipeline - Market report are Gene therapy, Small molecules, Stem cell therapy, Gene therapies

1 Market Overview
1.1 Macular Degeneration Drug Pipeline Product Introduction
1.2 Global Macular Degeneration Drug Pipeline Market Size Forecast
1.3 Macular Degeneration Drug Pipeline Market Trends & Drivers
1.3.1 Macular Degeneration Drug Pipeline Industry Trends
1.3.2 Macular Degeneration Drug Pipeline Market Drivers & Opportunity
1.3.3 Macular Degeneration Drug Pipeline Market Challenges
1.3.4 Macular Degeneration Drug Pipeline Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Macular Degeneration Drug Pipeline Players Revenue Ranking (2023)
2.2 Global Macular Degeneration Drug Pipeline Revenue by Company (2019-2024)
2.3 Key Companies Macular Degeneration Drug Pipeline Manufacturing Base Distribution and Headquarters
2.4 Key Companies Macular Degeneration Drug Pipeline Product Offered
2.5 Key Companies Time to Begin Mass Production of Macular Degeneration Drug Pipeline
2.6 Macular Degeneration Drug Pipeline Market Competitive Analysis
2.6.1 Macular Degeneration Drug Pipeline Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Macular Degeneration Drug Pipeline Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Gene therapy
3.1.2 Small molecules
3.1.3 Stem cell therapy
3.1.4 Gene therapies
3.2 Global Macular Degeneration Drug Pipeline Sales Value by Type
3.2.1 Global Macular Degeneration Drug Pipeline Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Macular Degeneration Drug Pipeline Sales Value, by Type (2019-2030)
3.2.3 Global Macular Degeneration Drug Pipeline Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Research Institute
4.1.3 Commercial
4.1.4 Other
4.2 Global Macular Degeneration Drug Pipeline Sales Value by Application
4.2.1 Global Macular Degeneration Drug Pipeline Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Macular Degeneration Drug Pipeline Sales Value, by Application (2019-2030)
4.2.3 Global Macular Degeneration Drug Pipeline Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Macular Degeneration Drug Pipeline Sales Value by Region
5.1.1 Global Macular Degeneration Drug Pipeline Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Macular Degeneration Drug Pipeline Sales Value by Region (2019-2024)
5.1.3 Global Macular Degeneration Drug Pipeline Sales Value by Region (2025-2030)
5.1.4 Global Macular Degeneration Drug Pipeline Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Macular Degeneration Drug Pipeline Sales Value, 2019-2030
5.2.2 North America Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Macular Degeneration Drug Pipeline Sales Value, 2019-2030
5.3.2 Europe Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Macular Degeneration Drug Pipeline Sales Value, 2019-2030
5.4.2 Asia Pacific Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Macular Degeneration Drug Pipeline Sales Value, 2019-2030
5.5.2 South America Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Macular Degeneration Drug Pipeline Sales Value, 2019-2030
5.6.2 Middle East & Africa Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value
6.3 United States
6.3.1 United States Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.3.2 United States Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.4.2 Europe Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.5.2 China Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.5.3 China Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.6.2 Japan Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.7.2 South Korea Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.8.2 Southeast Asia Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Macular Degeneration Drug Pipeline Sales Value, 2019-2030
6.9.2 India Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
6.9.3 India Macular Degeneration Drug Pipeline Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Amgen
7.1.1 Amgen Profile
7.1.2 Amgen Main Business
7.1.3 Amgen Macular Degeneration Drug Pipeline Products, Services and Solutions
7.1.4 Amgen Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.1.5 Amgen Recent Developments
7.2 Roche
7.2.1 Roche Profile
7.2.2 Roche Main Business
7.2.3 Roche Macular Degeneration Drug Pipeline Products, Services and Solutions
7.2.4 Roche Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.2.5 Roche Recent Developments
7.3 Adverum Biotechnologies
7.3.1 Adverum Biotechnologies Profile
7.3.2 Adverum Biotechnologies Main Business
7.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Products, Services and Solutions
7.3.4 Adverum Biotechnologies Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.3.5 AsclepiX Therapeutics Recent Developments
7.4 AsclepiX Therapeutics
7.4.1 AsclepiX Therapeutics Profile
7.4.2 AsclepiX Therapeutics Main Business
7.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
7.4.4 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.4.5 AsclepiX Therapeutics Recent Developments
7.5 Bioeq AG
7.5.1 Bioeq AG Profile
7.5.2 Bioeq AG Main Business
7.5.3 Bioeq AG Macular Degeneration Drug Pipeline Products, Services and Solutions
7.5.4 Bioeq AG Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.5.5 Bioeq AG Recent Developments
7.6 Sinocelltech
7.6.1 Sinocelltech Profile
7.6.2 Sinocelltech Main Business
7.6.3 Sinocelltech Macular Degeneration Drug Pipeline Products, Services and Solutions
7.6.4 Sinocelltech Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.6.5 Sinocelltech Recent Developments
7.7 RemeGen
7.7.1 RemeGen Profile
7.7.2 RemeGen Main Business
7.7.3 RemeGen Macular Degeneration Drug Pipeline Products, Services and Solutions
7.7.4 RemeGen Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.7.5 RemeGen Recent Developments
7.8 Grifols, S.A.
7.8.1 Grifols, S.A. Profile
7.8.2 Grifols, S.A. Main Business
7.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Products, Services and Solutions
7.8.4 Grifols, S.A. Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.8.5 Grifols, S.A. Recent Developments
7.9 Kyowa Kirin
7.9.1 Kyowa Kirin Profile
7.9.2 Kyowa Kirin Main Business
7.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Products, Services and Solutions
7.9.4 Kyowa Kirin Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.9.5 Kyowa Kirin Recent Developments
7.10 EyePoint Pharmaceutical
7.10.1 EyePoint Pharmaceutical Profile
7.10.2 EyePoint Pharmaceutical Main Business
7.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Products, Services and Solutions
7.10.4 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.10.5 EyePoint Pharmaceutical Recent Developments
7.11 IVERIC Bio
7.11.1 IVERIC Bio Profile
7.11.2 IVERIC Bio Main Business
7.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Products, Services and Solutions
7.11.4 IVERIC Bio Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.11.5 IVERIC Bio Recent Developments
7.12 Kodiak Sciences
7.12.1 Kodiak Sciences Profile
7.12.2 Kodiak Sciences Main Business
7.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Products, Services and Solutions
7.12.4 Kodiak Sciences Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.12.5 Kodiak Sciences Recent Developments
7.13 Ribomic
7.13.1 Ribomic Profile
7.13.2 Ribomic Main Business
7.13.3 Ribomic Macular Degeneration Drug Pipeline Products, Services and Solutions
7.13.4 Ribomic Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.13.5 Ribomic Recent Developments
7.14 Lineage Cell Therapeutics
7.14.1 Lineage Cell Therapeutics Profile
7.14.2 Lineage Cell Therapeutics Main Business
7.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
7.14.4 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.14.5 Lineage Cell Therapeutics Recent Developments
7.15 Graybug Vision
7.15.1 Graybug Vision Profile
7.15.2 Graybug Vision Main Business
7.15.3 Graybug Vision Macular Degeneration Drug Pipeline Products, Services and Solutions
7.15.4 Graybug Vision Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.15.5 Graybug Vision Recent Developments
7.16 CHABiotech
7.16.1 CHABiotech Profile
7.16.2 CHABiotech Main Business
7.16.3 CHABiotech Macular Degeneration Drug Pipeline Products, Services and Solutions
7.16.4 CHABiotech Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.16.5 CHABiotech Recent Developments
7.17 Shanghai Henlius Biotech
7.17.1 Shanghai Henlius Biotech Profile
7.17.2 Shanghai Henlius Biotech Main Business
7.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Products, Services and Solutions
7.17.4 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.17.5 Shanghai Henlius Biotech Recent Developments
7.18 Bio-Thera Solutions
7.18.1 Bio-Thera Solutions Profile
7.18.2 Bio-Thera Solutions Main Business
7.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Products, Services and Solutions
7.18.4 Bio-Thera Solutions Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.18.5 Bio-Thera Solutions Recent Developments
7.19 Alteogen
7.19.1 Alteogen Profile
7.19.2 Alteogen Main Business
7.19.3 Alteogen Macular Degeneration Drug Pipeline Products, Services and Solutions
7.19.4 Alteogen Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.19.5 Alteogen Recent Developments
7.20 Outlook Therapeutics
7.20.1 Outlook Therapeutics Profile
7.20.2 Outlook Therapeutics Main Business
7.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
7.20.4 Outlook Therapeutics Macular Degeneration Drug Pipeline Revenue (US$ Million) & (2019-2024)
7.20.5 Outlook Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Macular Degeneration Drug Pipeline Industrial Chain
8.2 Macular Degeneration Drug Pipeline Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Macular Degeneration Drug Pipeline Sales Model
8.5.2 Sales Channel
8.5.3 Macular Degeneration Drug Pipeline Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Macular Degeneration Drug Pipeline Market Trends
    Table 2. Macular Degeneration Drug Pipeline Market Drivers & Opportunity
    Table 3. Macular Degeneration Drug Pipeline Market Challenges
    Table 4. Macular Degeneration Drug Pipeline Market Restraints
    Table 5. Global Macular Degeneration Drug Pipeline Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Macular Degeneration Drug Pipeline Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Macular Degeneration Drug Pipeline Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Macular Degeneration Drug Pipeline Product Type
    Table 9. Key Companies Time to Begin Mass Production of Macular Degeneration Drug Pipeline
    Table 10. Global Macular Degeneration Drug Pipeline Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Macular Degeneration Drug Pipeline Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Macular Degeneration Drug Pipeline Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Macular Degeneration Drug Pipeline Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Macular Degeneration Drug Pipeline Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Macular Degeneration Drug Pipeline Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Macular Degeneration Drug Pipeline Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Macular Degeneration Drug Pipeline Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Macular Degeneration Drug Pipeline Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Macular Degeneration Drug Pipeline Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Macular Degeneration Drug Pipeline Sales Value by Region (2019-2024) & (%)
    Table 27. Global Macular Degeneration Drug Pipeline Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value, (2025-2030) & (US$ Million)
    Table 31. Amgen Basic Information List
    Table 32. Amgen Description and Business Overview
    Table 33. Amgen Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Amgen (2019-2024)
    Table 35. Amgen Recent Developments
    Table 36. Roche Basic Information List
    Table 37. Roche Description and Business Overview
    Table 38. Roche Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Roche (2019-2024)
    Table 40. Roche Recent Developments
    Table 41. Adverum Biotechnologies Basic Information List
    Table 42. Adverum Biotechnologies Description and Business Overview
    Table 43. Adverum Biotechnologies Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Adverum Biotechnologies (2019-2024)
    Table 45. Adverum Biotechnologies Recent Developments
    Table 46. AsclepiX Therapeutics Basic Information List
    Table 47. AsclepiX Therapeutics Description and Business Overview
    Table 48. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of AsclepiX Therapeutics (2019-2024)
    Table 50. AsclepiX Therapeutics Recent Developments
    Table 51. Bioeq AG Basic Information List
    Table 52. Bioeq AG Description and Business Overview
    Table 53. Bioeq AG Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Bioeq AG (2019-2024)
    Table 55. Bioeq AG Recent Developments
    Table 56. Sinocelltech Basic Information List
    Table 57. Sinocelltech Description and Business Overview
    Table 58. Sinocelltech Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Sinocelltech (2019-2024)
    Table 60. Sinocelltech Recent Developments
    Table 61. RemeGen Basic Information List
    Table 62. RemeGen Description and Business Overview
    Table 63. RemeGen Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of RemeGen (2019-2024)
    Table 65. RemeGen Recent Developments
    Table 66. Grifols, S.A. Basic Information List
    Table 67. Grifols, S.A. Description and Business Overview
    Table 68. Grifols, S.A. Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Grifols, S.A. (2019-2024)
    Table 70. Grifols, S.A. Recent Developments
    Table 71. Kyowa Kirin Basic Information List
    Table 72. Kyowa Kirin Description and Business Overview
    Table 73. Kyowa Kirin Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Kyowa Kirin (2019-2024)
    Table 75. Kyowa Kirin Recent Developments
    Table 76. EyePoint Pharmaceutical Basic Information List
    Table 77. EyePoint Pharmaceutical Description and Business Overview
    Table 78. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of EyePoint Pharmaceutical (2019-2024)
    Table 80. EyePoint Pharmaceutical Recent Developments
    Table 81. IVERIC Bio Basic Information List
    Table 82. IVERIC Bio Description and Business Overview
    Table 83. IVERIC Bio Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of IVERIC Bio (2019-2024)
    Table 85. IVERIC Bio Recent Developments
    Table 86. Kodiak Sciences Basic Information List
    Table 87. Kodiak Sciences Description and Business Overview
    Table 88. Kodiak Sciences Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Kodiak Sciences (2019-2024)
    Table 90. Kodiak Sciences Recent Developments
    Table 91. Ribomic Basic Information List
    Table 92. Ribomic Description and Business Overview
    Table 93. Ribomic Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Ribomic (2019-2024)
    Table 95. Ribomic Recent Developments
    Table 96. Lineage Cell Therapeutics Basic Information List
    Table 97. Lineage Cell Therapeutics Description and Business Overview
    Table 98. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Lineage Cell Therapeutics (2019-2024)
    Table 100. Lineage Cell Therapeutics Recent Developments
    Table 101. Graybug Vision Basic Information List
    Table 102. Graybug Vision Description and Business Overview
    Table 103. Graybug Vision Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Graybug Vision (2019-2024)
    Table 105. Graybug Vision Recent Developments
    Table 106. CHABiotech Basic Information List
    Table 107. CHABiotech Description and Business Overview
    Table 108. CHABiotech Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of CHABiotech (2019-2024)
    Table 110. CHABiotech Recent Developments
    Table 111. Shanghai Henlius Biotech Basic Information List
    Table 112. Shanghai Henlius Biotech Description and Business Overview
    Table 113. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Shanghai Henlius Biotech (2019-2024)
    Table 115. Shanghai Henlius Biotech Recent Developments
    Table 116. Bio-Thera Solutions Basic Information List
    Table 117. Bio-Thera Solutions Description and Business Overview
    Table 118. Bio-Thera Solutions Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Bio-Thera Solutions (2019-2024)
    Table 120. Bio-Thera Solutions Recent Developments
    Table 121. Alteogen Basic Information List
    Table 122. Alteogen Description and Business Overview
    Table 123. Alteogen Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Alteogen (2019-2024)
    Table 125. Alteogen Recent Developments
    Table 126. Outlook Therapeutics Basic Information List
    Table 127. Outlook Therapeutics Description and Business Overview
    Table 128. Outlook Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
    Table 129. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Outlook Therapeutics (2019-2024)
    Table 130. Outlook Therapeutics Recent Developments
    Table 131. Key Raw Materials Lists
    Table 132. Raw Materials Key Suppliers Lists
    Table 133. Macular Degeneration Drug Pipeline Downstream Customers
    Table 134. Macular Degeneration Drug Pipeline Distributors List
    Table 135. Research Programs/Design for This Report
    Table 136. Key Data Information from Secondary Sources
    Table 137. Key Data Information from Primary Sources
    Table 138. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Macular Degeneration Drug Pipeline Product Picture
    Figure 2. Global Macular Degeneration Drug Pipeline Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
    Figure 4. Macular Degeneration Drug Pipeline Report Years Considered
    Figure 5. Global Macular Degeneration Drug Pipeline Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Macular Degeneration Drug Pipeline Revenue in 2023
    Figure 7. Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Gene therapy Picture
    Figure 9. Small molecules Picture
    Figure 10. Stem cell therapy Picture
    Figure 11. Gene therapies Picture
    Figure 12. Global Macular Degeneration Drug Pipeline Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 13. Global Macular Degeneration Drug Pipeline Sales Value Market Share by Type, 2023 & 2030
    Figure 14. Product Picture of Hospital
    Figure 15. Product Picture of Research Institute
    Figure 16. Product Picture of Commercial
    Figure 17. Product Picture of Other
    Figure 18. Global Macular Degeneration Drug Pipeline Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Macular Degeneration Drug Pipeline Sales Value Market Share by Application, 2023 & 2030
    Figure 20. North America Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
    Figure 21. North America Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
    Figure 22. Europe Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
    Figure 23. Europe Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
    Figure 24. Asia Pacific Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
    Figure 25. Asia Pacific Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
    Figure 26. South America Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
    Figure 27. South America Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
    Figure 28. Middle East & Africa Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
    Figure 29. Middle East & Africa Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
    Figure 30. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value (%), (2019-2030)
    Figure 31. United States Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 32. United States Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 33. United States Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 34. Europe Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 35. Europe Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 36. Europe Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 37. China Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 38. China Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 39. China Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 40. Japan Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Japan Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 42. Japan Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 43. South Korea Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 44. South Korea Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 45. South Korea Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 46. Southeast Asia Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 48. Southeast Asia Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 49. India Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
    Figure 50. India Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
    Figure 51. India Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
    Figure 52. Macular Degeneration Drug Pipeline Industrial Chain
    Figure 53. Macular Degeneration Drug Pipeline Manufacturing Cost Structure
    Figure 54. Channels of Distribution (Direct Sales, and Distribution)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Disposable Medical Protective Wear Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-24Q7462
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Add to Cart

Comprehensive Ophthalmology Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-3X18805
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global 3-Ply Medical Surgical Mask Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-3N7947
Thu Dec 12 00:00:00 UTC 2024

Add to Cart